Medical professionals, medical students, ACTUP New York, and their supporters held a rousing protest rally outside Pfizer World Headquarters in New York. At the beginning of this year, the corporate giant announced price increases for 40 of its drugs. (Photo: Erik McGregor/Pacific Press/LightRocket via Getty
Corporations’ quest for profits is what “is driving up drug prices and nothing more.”
That’s according to Dennis Bourdette, M.D., chair of neurology in the Oregon Health and Science University (OHSU) School of Medicine, who co-authored a study published Monday that sought to find out companies’ rationale for the escalating prices on medications for patients with multiple sclerosis.
Prices for those drugs, an accompanying press release notes, have jumped up by 10% to 15% every year for the past decade.
The study by a team of researchers at OHSU and the OHSU/Oregon State University College of Pharmacy, which appears in the journal Neurology this month, was based on interviews with four current and former pharmaceutical industry executives who had direct involvement in the pricing or marketing of MS drugs.
The executives, who were not named, laid […]
Such profits should be eliminated in a “Medicare-for-All” type of system which includes a non-profit making deal with the pharmaceutical companies.